Radioiodine Refractory Differentiated Thyroid Cancer: Time to Update the Classifications
Author:
- 1 September 2018
- journal article
- research article
- Published by SAGE Publications in Thyroid®
- Vol. 28 (9) , 1083-1093
Abstract
The management of aggressive and progressing metastatic differentiated thyroid cancer (DTC) is very difficult, and the determination as to when such patients are refractory to 131 I therapy (e.g. radioiodine refractory) is problematic and controversial. Objective: The objective of this review is to discuss 1) the present major classifications of radioiodine refractory disease in DTC, 2) factors that should be considered before designating a patient’s DTC as radioiodine refractory, 3) potential approaches and caveats to help manage and minimize a patient’s exclusion from an 131I therapy that may have potential benefit in patients with aggressive and progressing metastatic DTC, 4) next steps for revision of the classifications of radioiodine refractory DTC, and 5) areas for future research. Summary To date, the classifications of radioiodine refractory DTC, although very useful, are not sacrosanct especially in the context of individualized patient management, and merely because a patient meets one or more of the various classifications, one should not consider by definition, fiat, or de facto that that patient’s DTC is radioiodine refractory. Rather, each patient should be individually managed with a good understanding of the limitations of the various classifications and potential approaches to help manage that patient. With awareness of the suggestions and caveats discussed herein and with assessment of the many other factors that affect the patient’s specific clinical situation, the managing physician can deliver appropriate individualized patient care. A multi-organizational committee should be established as a standing committee to supervise and assist in the update of the classifications of radioiodine refractory DTC including discussions of their limitations. Conclusion Radioiodine refractory classifications will continue to evolve as 1) more studies are published, 2) managing physicians better understand the limitations and confounding factors of present classifications, and 3) new agents either increase or re-establish I-131 uptake.Keywords
This publication has 38 references indexed in Scilit:
- 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid CancerThyroid®, 2016
- A new appraisal of iodine refractory thyroid cancerEndocrine-Related Cancer, 2015
- Definition and management of radioactive iodine-refractory differentiated thyroid cancerThe Lancet Diabetes & Endocrinology, 2014
- Evolving Approaches in Managing Radioactive Iodine-Refractory Differentiated Thyroid CancerEndocrine Practice, 2014
- Clinical Outcomes and Molecular Profile of Differentiated Thyroid Cancers With Radioiodine-Avid Distant MetastasesThe Journal of Clinical Endocrinology & Metabolism, 2013
- Clinical Outcomes Following Empiric Radioiodine Therapy in Patients with Structurally Identifiable Metastatic Follicular Cell–Derived Thyroid Carcinoma with Negative Diagnostic But Positive Post-Therapy 131 I Whole-Body ScansThyroid®, 2012
- Regional approaches to the management of patients with advanced, radioactive iodine-refractory differentiated thyroid carcinomaExpert Review of Anticancer Therapy, 2012
- ENDOCRINE TUMOURS: Approach to the patient with advanced differentiated thyroid cancerEuropean Journal of Endocrinology, 2012
- GEMOX regimen in the treatment of metastatic differentiated refractory thyroid carcinomaMedical Oncology, 2011
- Long-Term Outcome of 444 Patients with Distant Metastases from Papillary and Follicular Thyroid Carcinoma: Benefits and Limits of Radioiodine TherapyThe Journal of Clinical Endocrinology & Metabolism, 2006